A drug developed at Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) in collaboration with biopharma venture partner Acerta Pharma benefited from FDA approval as a first-line...